0
Abstract: Poster Presentations |

SERUM KL-6 DURING ACUTE REJECTION EPISODES AFTER LUNG TRANSPLANTATION FREE TO VIEW

Minh L. Doan, MD*; Joseph N. Walter, MD; Haibin Zhang, MD; Leland L. Fan, MD; George B. Mallory, MD, FCCP; Okan Elidemir, MD, FCCP
Author and Funding Information

Baylor College of Medicine, Houston, TX



Chest. 2006;130(4_MeetingAbstracts):235S. doi:10.1378/chest.130.4_MeetingAbstracts.235S-b
Text Size: A A A
Published online

Abstract

PURPOSE: KL-6 is a glycoprotein expressed on type 2 pneumocytes and respiratory bronchiolar epithelial cells. Serum KL-6 levels have been shown to be elevated in various interstitial lung diseases and correlate with disease activity. We previously reported that serum KL-6 levels were elevated in lung transplant recipients with chronic airway rejection [bronchiolitis obliterans syndrome (BOS)], when compared to recipients who did not have this complication. We therefore concluded that serum KL-6 levels could be used as a diagnostic tool for non-invasive detection of BOS. The drop in lung function that can occur with acute rejection episodes can confound the diagnosis of BOS. Thus, a need to evaluate how serum KL-6 levels would change during acute rejection episodes has emerged. The pathology of acute rejection occurs predominantly around the blood vessels without involvement of the airways or the alveoli where KL-6 is localized. Therefore, we hypothesized that serum KL-6 levels would not be elevated during episodes of acute rejection in lung transplant recipients.

METHODS: To test our hypothesis, we collected blood samples from patients undergoing transbronchial lung biopsy (TBB) for surveillance and measured serum KL-6 levels by ELISA. Lung transplant recipients who had BOS or other conditions known to cause elevations of KL-6 were excluded. Mean (±SD) KL-6 levels were calculated for biopsies without rejection and were compared with means for biopsies showing different grades of rejection by using T-test.

RESULTS: A total of 68 samples were collected from 34 patients. The mean serum KL-6 for biopsies without rejection (A0) was 260±129 U/mL, while levels for A1 and A2+A3 rejections were 218±79 U/mL and 231±91 U/mL, respectively. There were no statistically significant differences between the A0 group and any of the other 2 groups (p>0.1 for both comparisons).

CONCLUSION: Our results indicate that serum KL-6 levels do not elevate with episodes of acute vascular rejection in lung transplant recipients.

CLINICAL IMPLICATIONS: Thus, serum KL-6 carries the potential to be a specific test for screening of chronic airway rejection.

DISCLOSURE: Minh Doan, None.

Wednesday, October 25, 2006

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543